Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson’s Disease
暂无分享,去创建一个
J. Shan | P. Silburn | A. Mackay-Sim | S. Ravishankar | N. Matigian | J. Neuzil | S. Wood | A. Cook | G. Mellick | M. Murtaza | N. Matigian | M. Todorovic | A. L. Cook | S. Ravishankar | L. F. Dong | J. Neuzil | P. Silburn | A. Mackay-Sim | G. D. Mellick | S. A. Wood | M. Murtaza | M. Todorovic | J. Shan | L. Dong
[1] Rudolf Jaenisch,et al. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.
[2] D. Turnbull,et al. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.
[3] C. Chinopoulos,et al. Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease , 2001, Journal of neurochemistry.
[4] H. Reichmann,et al. Primary Skin Fibroblasts as a Model of Parkinson's Disease , 2012, Molecular Neurobiology.
[5] Christine A. Wells,et al. NRF2 Activation Restores Disease Related Metabolic Deficiencies in Olfactory Neurosphere-Derived Cells from Patients with Sporadic Parkinson's Disease , 2011, PloS one.
[6] C. Marsden,et al. L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain , 1995, Movement disorders : official journal of the Movement Disorder Society.
[7] H. Shill,et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.
[8] Hideyuki Okano,et al. iPS cell technologies: significance and applications to CNS regeneration and disease , 2014, Molecular Brain.
[9] R. Schiestl,et al. Transcriptome Analysis of a Rotenone Model of Parkinsonism Reveals Complex I-Tied and -Untied Toxicity Mechanisms Common to Neurodegenerative Diseases , 2012, PloS one.
[10] W. Mandemakers,et al. A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases , 2007, Journal of Cell Science.
[11] M. Vila,et al. Mitochondrial alterations in Parkinson’s disease: new clues , 2008, Journal of neurochemistry.
[12] K. Shannon,et al. Alpha‐synuclein in colonic submucosa in early untreated Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[13] M. Beal,et al. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.
[14] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[15] F. Jiménez-Jiménez,et al. Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease , 2010, BMC neurology.
[16] A. Mackay-Sim,et al. New techniques for biopsy and culture of human olfactory epithelial neurons. , 1998, Archives of otolaryngology--head & neck surgery.
[17] Victor Tapias,et al. A highly reproducible rotenone model of Parkinson's disease , 2009, Neurobiology of Disease.
[18] C. Broeckhoven,et al. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria? , 2008, Genes, brain, and behavior.
[19] N. Osborne,et al. Partial mitochondrial complex I inhibition induces oxidative damage and perturbs glutamate transport in primary retinal cultures. Relevance to Leber Hereditary Optic Neuropathy (LHON) , 2006, Neurobiology of Disease.
[20] R. Benecke,et al. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. , 1993, Brain : a journal of neurology.
[21] A. Brice,et al. What genetics tells us about the causes and mechanisms of Parkinson's disease. , 2011, Physiological reviews.
[22] C. Concannon,et al. On the role of Hsp27 in regulating apoptosis , 2004, Apoptosis.
[23] C. Wells,et al. Disease-specific, neurosphere-derived cells as models for brain disorders , 2010, Disease Models & Mechanisms.
[24] C. Olanow,et al. The pathogenesis of cell death in Parkinson's disease , 2006, Neurology.
[25] Ted M. Dawson,et al. Genetic Animal Models of Parkinson's Disease , 2010, Neuron.
[26] Guido Kroemer,et al. Hsp27 negatively regulates cell death by interacting with cytochrome c , 2000, Nature Cell Biology.
[27] Mancheva-Ganeva Velina,et al. Licensed under Creative Commons Attribution Cc by Oxidative Stress in Parkinson's Disease , 2022 .
[28] A. Mackay-Sim,et al. Isolation of adult stem cells from the human olfactory mucosa. , 2013, Methods in molecular biology.
[29] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[30] M. Beal,et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.
[31] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[32] P. Srivastava,et al. Heat‐Shock Proteins , 2003, Current protocols in immunology.
[33] E. Parati,et al. Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease. , 1993, Biochemical medicine and metabolic biology.
[34] M. Farrer. Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.
[35] K. Schulze-Osthoff,et al. Small Stress Proteins as Novel Regulators of Apoptosis , 1996, The Journal of Biological Chemistry.
[36] W. Kunz,et al. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients , 2004, Journal of the Neurological Sciences.
[37] C. Moraes,et al. Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology* , 1999, The Journal of Biological Chemistry.
[38] Michaela E Johnson,et al. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. , 2015, Neurotoxicology.
[39] A. J. Lambert,et al. Inhibitors of the Quinone-binding Site Allow Rapid Superoxide Production from Mitochondrial NADH:Ubiquinone Oxidoreductase (Complex I)* , 2004, Journal of Biological Chemistry.
[40] Philip L De Jager,et al. Parkinson's disease: genetics and pathogenesis. , 2011, Annual review of pathology.
[41] A. Schapira,et al. Mitochondrial Contribution to Parkinson's Disease Pathogenesis , 2011, Parkinson's disease.
[42] W. Kunz,et al. Detection of Respiratory Chain Defects in Cultivated Skin Fibroblasts and Skeletal Muscle of Patients with Parkinson's Disease , 1999, Annals of the New York Academy of Sciences.
[43] L. Montero,et al. Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology , 2009, Neurobiology of Disease.
[44] O. Blin,et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy , 1994, Journal of the Neurological Sciences.
[45] T. Nishioka,et al. Mode of inhibitory action of Deltalac-acetogenins, a new class of inhibitors of bovine heart mitochondrial complex I. , 2006, Biochemistry.
[46] Piu Chan,et al. Epidemiology of Parkinson's disease , 2016 .
[47] E. Solary,et al. HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[48] J. Langston,et al. The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.
[49] N. Hattori,et al. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.
[50] A. Kurz,et al. Parkinson patient fibroblasts show increased alpha-synuclein expression , 2008, Experimental Neurology.
[51] J. Parks,et al. Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.
[52] N. Wood,et al. Expanding insights of mitochondrial dysfunction in Parkinson's disease , 2006, Nature Reviews Neuroscience.
[53] E. Schon,et al. Mitochondria: The Next (Neurode)Generation , 2011, Neuron.
[54] M. Yahr,et al. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[55] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[56] W. Tatton,et al. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy? , 1998, Annals of neurology.
[57] Patrick A. Lewis,et al. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus , 2011, Nature communications.
[58] A. Brice,et al. Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.
[59] J. Langston,et al. Can cellular models revolutionize drug discovery in Parkinson's disease? , 2009, Biochimica et biophysica acta.
[60] C. Páyan-Gomez,et al. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. , 2014, Biochimica et biophysica acta.
[61] A. Schapira,et al. Test for LRRK2 mutations in patients with Parkinson’s disease , 2008, Practical Neurology.
[62] B. Chauffert,et al. HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. , 1997, Cancer research.
[63] M. Beal,et al. Mitochondria take center stage in aging and neurodegeneration , 2005, Annals of neurology.
[64] M. Memo,et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease , 2012, EMBO molecular medicine.